Налмефен - новый препарат для лечения алкогольной зависимости в режиме «по требованию»


Цитировать

Полный текст

Открытый доступ Открытый доступ
Доступ закрыт Доступ предоставлен
Доступ закрыт Доступ платный или только для подписчиков

Аннотация

Статья посвящена обзору результатов клинических исследований нового препарата для лечения алкогольной зависимости в режиме «по требованию». В отличие от классических подходов к лечению алкоголизма, направленных на достижение полной абстиненции и предотвращение рецидивов потребления алкоголя, альтернативный подход предполагает постепенное снижение количества потребляемого этанола за счет применения препарата в режиме «по требованию». В качестве препарата выбора для альтернативного подхода клечению алкоголизма рассмотрен налмефен. Приведены доказательные данные, подтверждающие, что налмефен является эффективным препаратом для снижения потребления алкоголя пациентами с алкогольной зависимостью, не желающими полностью прекратить потребление этанола.

Полный текст

Доступ закрыт

Об авторах

Е. А Ушкалова

РУДН

Email: eushk@yandex.ru
д.м.н., проф. кафедры общей и клинической фармакологии Москва

А. В Ушкалова

Европейский медицинский центр

к.м.н., врач-психиатр, отделение психиатрии и психотерапии Москва

Список литературы

  1. Van den Brink W., Aubin H.J., Bladström A., Bladström A., Torup L., Gual A., Mann K. Efficacy of as-needed nalmefene in alcohol-dependent patients with at least a high drinking risk level: results from a subgroup analysis of two randomized controlled 6-month studies. Alcohol Alcohol. 2013;48(6): 570-78.
  2. Sinclair J., Batel P., Kiefer F. As-needed us of nalmefene in the treatment of alcohol dependence (poster). 21st European Congress of Psychiatry; 6-9 Apr 2013; Nice
  3. van den Brink W., Sorensen P., Torup L., Mann K., Gual A; for the SENSE Study Group. Long-term efficacy, tolerability and safety of nalmefene as-needed in patients with alcohol dependence: A 1-year, randomised controlled study. J. Psychopharmacol. 2014;28(8):733-44.
  4. van den Brink W., Strang J., Gual A., Srensen P., Jensen T.J., Mann K. Safety and tolerability of as-needed nalmefene in the treatment of dependence: results from the Phase III clinical programme. Expert. Opin. Drug Saf. 2015 Feb 4:1-10. [Epub ahead of print].o
  5. Keating G.M. Nalmefene: a review of its use in the treatment of alcohol dependence. CNS Drugs. 2013;27(9):761-72.
  6. Anderson P., Baumberg B. (2006). Alcohol in Europe - A public health perspective. A report for the European Commission. England: Institute of Alcohol Studies.
  7. Thavorncharoensap M., Teerawattananon Y., Yothasamut J., Lertpitakpong C., Chaikledkaew U. The economic impact of alcohol consumption: a systematic review. Subst Abuse Treat Prev Policy. 2009;4:20.
  8. Dawson D.A., Goldstein R.B., Saha T.D.,Grant B.F. Changes in alcohol consumption: United States, 2001-2002 to 2012-2013. Drug Alcohol. Depend. 2014 Dec 23 [Epub ahead of print]
  9. McGlynn E.A., Asch S.M., Adams J., Keesey J., Hicks J., DeCristofaro A., Kerr E.A. The quality of health care delivered to adults in the United States. N. Engl. J. Med. 2003;348(26):2635-645.
  10. Kohn R, Saxena S, Levav I, Saraceno B. The treatment gap in mental health care. Bull World Health Organ. 2004;82(11):858-66.
  11. Alonso J., Angermeyer M.C., Bernert S., Bruffaerts R., Brugha T.S., Bryson H., de Girolamo G., Graaf R., Demyttenaere K., Gasquet I,. Haro J.M., Katz S.J., Kessler R.C., Kovess V., Lepine J.P., Ormel J., Polidori G., Russo L.J., Vilagut G, Almansa J., Arbabzadeh-Bouchez S., Autonell J., Bernal M., Buist-Bouwman M.A., Codony M., Domingo-Salvany A., Ferrer M., Joo S.S., Martinez-Alonso M., Matschinger H., Mazzi F., Morgan Z., Morosini P., Palacin C., Romera B., Taub N., Vollebergh W.A. ESEMeD/MHEDEA 2000 Investigators, European Study of the Epidemiology of Mental Disorders (ESEMeD) Project. Use of mental health services in Europe: results from the European Study of the Epidemiology of Mental Disorders (ESEMeD) project. Acta Psychiatr. Scand. Suppl. 2004;420:47-54.
  12. Grant B.F. Barriers to alcoholism treatment: reasons for not seeking treatment in a general population sample. J. Stud.Alcohol. 1997;58(4): 365-71.
  13. Aubin H.J., Daeppen J.B. Emerging pharmacotherapies for alcohol dependence: a systematic review focusing on reduction in consumption. Drug Alcohol. Depend. 2013;133(1):15-29.
  14. Hodgins D.C., Leigh G., Milne R., Gerrish R. Drinking goal selection in behavioral selfmanagement treatment of chronic alcoholics. Addictive Behaviors. 1997; 22(2):247-55.
  15. Heather N., Adamson S.J., Raistrick D. Initial preference for drinking goal in the treatment of alcohol problems: I. Baseline differences between abstinence and non-abstinence groups. Alcohol Alcohol. 2010;45(2):128-35.
  16. European Medicines Agency. Guideline on the development of medicinal products for the treatment of alcohol dependence. 2010. http:// www.ema.europa.eu/docs/en_GB/docu-ment_library/ Scientific_guideline/2010/03/ WC500074898.pdf.
  17. Luquiens A., Reynaud M., Aubin H.J. Is controlled drinking an acceptable goal in the treatment of alcohol dependence? A survey of French alcohol specialists. Alcohol Alcohol. 2011; 46(5):586-91.
  18. European Medicines Agency. Selincro (nalmefene): EU summary of product characteristics. 2013. http://www.emea.europa. eu/docs/en_GB/document_library/EPAR_-_ Product_Information/human/002583/ WC500140255.pdf.
  19. France C.P., Gerak L.R. Behavioral effects of 6-methylene naltrexone (nalmefene) in rhesus monkeys. J. Pharmacol. Exp. ФАРМАТЕКА № 9 - 2015
  20. ■ НОВЫЕ ЛЕКАРСТВЕННЫЕ СРЕДСТВА И ПОДХОДЫ К ЛЕЧЕНИЮ Ther.1994;270(3):992-99.
  21. Bart G., Schluger J.H., Borg L., Ho A., Bidlack J.M., Kreek M.J. Nalmefene induced elevation in serum prolactin in normal human volunteers: partial kappa opioid agonist activity? Neuropsychopharmacology. 2005;30(12):2254-62.
  22. Gianoulakis C. Influence of the endogenous opioid system on high alcohol consumption and genetic predisposition to alcoholism. J. Psychiatry Neurosci. 2001;26(4):304-18.
  23. Chefer V.I., Czyzyk T., Bolan E.A., Moron J., Pintar J.E., Shippenberg T.S. Endogenous kappaopioid receptor systems regulate mesoaccumbal dopamine dynamics and vulnerability to cocaine. J. Neurosci. 2005;25(20):5029-37.
  24. Shippenberg T.S., Zapata A., Chefer V.I. Dynorphin and the pathophysiol-ogy of drug addiction. Pharmacol Ther. 2007;116(2):306-321.
  25. EMA-CHMP. Selincro Assessment report, December 13, 2012. Available from: http:// www.ema.europa.eu/docs/en_GB/document_ library/EPAR_ _Public_assessment_report/ human/002583/WC500140326.pdf.
  26. Ingman K., Hagelberg N., Aalto S., Nagren K., Juhakoski A, Karhuvaara S., Kallio A., Oikonen V., Hietala J., Scheinin H. Prolonged central μ-opioid receptor occupancy after single and repeated nalmefene dosing. Neuropsychopharmacology. 2005;30(12):2245-53.
  27. Fudala P.J., Heishman S.J., Henningfield J.E., Johnson R.E. Human pharmacology and abuse potential of nalmefene. Clin Pharmacol Ther. 1991;49(3):300-06.
  28. Paille F., Martini H. Nalmefene: a new approach to the treatment of alcohol dependence. Subst Abuse Rehabil. 2014 Aug 8;5:87-94.
  29. June H.L., Grey С., Warren-Reese C., Durr L.F., Ricks-Cord A., Johnson A., McCane S., Williams L.S, Mason D., Cummings R., Lawrence A. The opioid receptor antagonist nalmefene reduces responding maintained by ethanol presentation: preclinical studies in ethanol-preferring and outbred Wistar rats. Alcohol. Clin. Exp. Res. 1998;22(9):2174-85.
  30. June H.L., Cummings R., Eiler W.J.A., Foster K.L., McKay P.F., Seyoum R., Garcia M., McCane S., Grey C., Hawkins S.E., Mason D. Central opioid receptors differentially regulate the nalmefene-induced suppression of ethanol-and saccharin-reinforced behaviors in alcohol-preferring (P) rats. Neuropsychopharmacology. 2004;29(2):285-99.
  31. Walker B.M., Koob G.F. Pharmacological evidence for a motivational role of κ-opioid systems in ethanol dependence. Neuropsychopharmacology. 2008;33(3):643-52.
  32. Nealey K.A., Smith A.W., Davis S.M., Smith D.G., Walker B.M. κ-opioid receptors are implicated in the increased potency of intra-accumbens nalmefene in ethanol-dependent rats. Neuropharmacology. 2011;61(1-2):35-42.
  33. Kissler J.L., Sirohi S., Reis D.J., Jansen H.T., Quock R.M., Smith D.G., Walker B.M. The one-two punch of alcoholism:role of central amygdala dynorphins/kappa-opioid receptors. 2014;75(10):774-82.
  34. Mason B.J., Ritvo E.C., Morgan R.O., Salvato F.R., Goldberg G., Welch B., Mantero-Atienza E. A double-blind, placebo-controlled pilot study to evaluate the efficacy and safety of oral nalmefene HCl for alcohol dependence. Alcohol. Clin. Exp. Res. 1994;18(5): 1162-167.
  35. Mason B.J., Salvato F.R., Williams L.D., Ritvo E.C., Cutler R.B. A double-blind, placebo-controlled study of oral nalmefene for alcohol dependence. Arch Gen Psychiatry. 1999;56(8):719-24.
  36. Anton R.F., Pettinati H., Zweben A., Kranzler H.R., Johnson B., Bohn M.J., McCaul M.E., Anthenelli R. Salloum I,. Galloway G., Garbutt J., Swift R., Gastfriend D., Kallio A., Karhuvaara S. A multisite dose ranging study of nalmefene in the treatment of alcohol dependence. J. Clin. Psychopharmacol. 2004;24(4):421-28.
  37. Karhuvaara S., Simojoki K., Virta A., Rosberg M., Löyttyniemi E., Nurminen T., Kallio A., Makela R. Targeted nalmefene with simple medical management in the treatment of heavy drinkers: a randomized double-blind placebo-controlled multicenter study. Alcohol. Clin. Exp. Res. 2007;31(7):1179-187.
  38. Volpicelli J.R., Pettinati H.M., McLellan A.T., O'Brien C.P. Enhanced Medication and Treatment Adherence for Addiction Treatment. The BRENDA Model. New York, NY, USA: Guilford Press; 2001.
  39. Starosta A.N., Leeman R.F., Volpicelli J.R. The BRENDA model: integrating psychosocial treatment and pharmacotherapy for the treatment of alcohol use disorders. J. Psychiatr. Pract. 2006;12(2):80-89.
  40. Mann K., Bladström A., Torup L., Gual A., van den Brink W. Extending the treatment options in alcohol dependence: a randomized controlled study of as-needed nalmefene. Biol. Psychiatry. 2013;73(8):706-13.
  41. Gual A., He Y., Torup L., van den Brink W., Mann K; ESENSE 2 Study Group. A randomised, double-blind, placebo-controlled, efficacy study of nalmefene, as-needed use, in patients with alcohol dependence. Eur Neuropsychopharmacol. 2013;23(11): 1432-42.
  42. Wittchen H.U., Jacobi F., Rehm J., Gustavsson A., Svensson M., Jönsson B., OlesenJ., Allgulander C., Alonso J,. Faravelli C., Fratiglioni L., Jennum P., Lieb R., Maercker A., van Os J., Preisig M., Salvador-Carulla L., Simon R., Steinhausen H.C. The size and burden of mental disorders and other disorders of the brain in Europe 2010. Eur. Neuropsychopharmacol. 2011;21(9):655-79.
  43. National Institute for Health and Clinical Excellence. Alcohol use disorders: diagnosis, assessment and management of harmful drinking and alcohol dependence. 2011. http://www.nice.org.uk/nicemedia/ live/13337/53191/53191.pdf.
  44. Rehm J., Baliunas D., Borges G.L.G., Graham K., Irving H., Kehoe T., Parry C.D., Patra J., Popova S., Poznyak V., Roerecke M., Room R., Samokhvalov A.V., Taylor B. The relation between different dimensions of alcohol consumption and burden of disease: an overview. Addiction. 2010;105(5):817-43.
  45. Global status report on alcohol and health 2014. http://apps.who.int/iris/bitstre am/10665/112736/1/9789240692763_eng.pdf?ua=1
  46. Rehm J., Shield K., Gmel G., Rehm M.X., Frick U. Modeling the impact of alcohol dependence on mortality burden and the effect of available treatment interventions in the European Union. Eur. Neuropsychopharmacol 2013; 23(2):89-97.
  47. Rehm J., Mathers C., Popova S. , Thavorncharoensap M., Teerawattananon Y., Patra J. Global burden of disease and injury and economic cost attributable to alcohol use and alcohol-use disorders. Lancet 2009;373 (9682):2223-33.
  48. Кошкина Е. Л., Паронян И. Д. Павловская Н.И. Оценка алкогольной ситуации в России. РМЖ. 1996;3(7):421-24

Дополнительные файлы

Доп. файлы
Действие
1. JATS XML
Скачать

© ООО «Бионика Медиа», 2015

Данный сайт использует cookie-файлы

Продолжая использовать наш сайт, вы даете согласие на обработку файлов cookie, которые обеспечивают правильную работу сайта.

О куки-файлах